Published : 05/31/2019  -  Categories : News

Alsachim has developed a new Tyrosine Kinase Inhibitors stable labeled standards, you can now get access to these standards to boost your research.

Tyrosine Kinase inhibitors have always been at the core of cancer research. They enable targeted therapy aimed against cancer-specific molecules and signaling pathways with utterly limited nonspecific toxicities.

Brigatinib is a next generation anaplastic lymphoma kinase inhibitor (ALK). It has a proven efficacy in patient with ALK positive non-small-cell lung cancer. The food and drug administration has granted the accelerated approval for Brigatinib in April 2018 and research around this standard has been rising.

Click here to download the product sheet

Contact us now to get more information and a personalized quote.

Search on news

News archives